MYGN: Myriad Genetics Inc Company Value to Net Income

Corporate emblem and logo of Myriad Genetics Corp (MYGN)

Optimizing IT infrastructure through cloud partners while maintaining an internal R&D center stabilizes the efficiency of Myriad Genetics, Inc. (MYGN). The company's monthly P/E dynamics confirm this resilience, and -4.20 captures the current state of the parameter. Growth is driven by patents and leadership in psychiatric testing, while high-precision laboratories in the US guarantee the accuracy of personalized diagnostics.

Myriad Genetics Inc (MYGN): Price to Earnings Ratio from 07/04/2022 to 11/14/2026

Analytical breakdowns for Myriad Genetics, Inc.

- share price and expert price forecast:
Price Performance Chart Myriad Genetics Corp|MYGN - Consensus Target
- market capitalization information:
Market Value Myriad Genetics Inc|MYGN - Enterprise Value
- balance sheet net asset value indicators:
Book Value per Share Myriad Genetics|MYGN - Company Book Value|Capitalization to Book Value Ratio myriad.com|MYGN - Company Total Assets
- debt and solvency information:
Total Debt to Capital Myriad Genetics, Inc.|MYGN - Long-Term Debt to Equity|Short-Term Debt to Equity Myriad Genetics|MYGN - Company Total Debt|Debts to Book Value Myriad Genetics Corp|MYGN - Company Long-Term Debt|Short-Term Debt Volume Myriad Genetics|Interim Coverage Ratio myriad.com
- net income and valuation ratios data:
MYGN - Company Net Income|Company Profit Forecast Myriad Genetics, Inc.|MYGN - Price to Earnings Ratio|Projected Price to Earnings Myriad Genetics, Inc.|MYGN - Price/Earnings to Growth Multiple|Company Value to EBITDA Myriad Genetics Corp|MYGN - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year Myriad Genetics|MYGN - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months myriad.com|MYGN - Earnings growth in current year|Earnings growth forecast for next year Myriad Genetics, Inc.
- sales volume and revenue indicators:
MYGN - Revenue and Sales Volume|Company Revenue Forecast Myriad Genetics Corp|MYGN - Market Cap to Revenue|Forward Price to Sales Myriad Genetics Inc
General company analysis:MYGN (Myriad Genetics Inc)
Core merchandise of Myriad

For Myriad Genetics, Inc. (MYGN), a molecular diagnostics pioneer with a unique array of genetic patents, the price-to-earnings ratio serves as a gauge of market expectations. By analyzing the P/E ratio, an investor determines the number of years required for capital recovery through current earnings, which allows for a comparison of GeneSight therapy's value against the actual monetization rates of intellectual capital and the resilience of the business model.

Analysis of competing companies

CAI: Company Value to Net Income|Price to Earnings Ratio Guardant Health, Inc. (GH)|VCYT (Veracyte Corp) - Company Value to Net Income|P/E Multiple CELC (Celcuity Therapeutics)|P/E Multiple grail.com GRAL|CSTL - Price to Earnings Ratio|BNR - P/E Multiple|VNRX: P/E Multiple|Biodesix Corporation (BDSX) - P/E Multiple|Price to Earnings Ratio Precipio, Inc.|Price to Earnings Ratio CHEK|Price to Earnings Ratio MYNZ (Mainz Biomed NV)|Business Payback Period OncoCyte